Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
MVX-ONCO-1 / Release Therap
SAKK 11/16, NCT02999646: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC	Completed	2	16	Europe	MVX-ONCO-1	Maxivax SA, European Commission	Head and Neck Squamous Cell Carcinoma	01/23	06/23
MVX-2011-01, NCT02193503: MVX-ONCO-1 in Patients With Solid Tumor	Active, not recruiting	1	34	Europe	Treatment, - capsules MVX-1-loaded (medical device), - irradiated autologous tumor cells (cell therapy)	Maxivax SA	Solid Tumor, Cancer	03/22	12/26
MVX-ONCO-2 / MaxiVAX
NCT05071846: MVX-ONCO-2 in Advanced Solid Tumors	Recruiting	1	6	Europe	MVX-ONCO-2	University Hospital, Geneva, CATO-SMS	Solid Tumor, Adult	10/25	10/29
MVX-ONCO-3 / Release Therap
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
MVX-ONCO-1 / Release Therap
SAKK 11/16, NCT02999646: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC	Completed	2	16	Europe	MVX-ONCO-1	Maxivax SA, European Commission	Head and Neck Squamous Cell Carcinoma	01/23	06/23
MVX-2011-01, NCT02193503: MVX-ONCO-1 in Patients With Solid Tumor	Active, not recruiting	1	34	Europe	Treatment, - capsules MVX-1-loaded (medical device), - irradiated autologous tumor cells (cell therapy)	Maxivax SA	Solid Tumor, Cancer	03/22	12/26
MVX-ONCO-2 / MaxiVAX
NCT05071846: MVX-ONCO-2 in Advanced Solid Tumors	Recruiting	1	6	Europe	MVX-ONCO-2	University Hospital, Geneva, CATO-SMS	Solid Tumor, Adult	10/25	10/29
MVX-ONCO-3 / Release Therap
No trials found